Attovia Therapeutics, Inc.

ATTO

Insiders bought in the last twelve months.

13.73 1.05 −7.10%
Market cap
$674.7M
P/E
—
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a

Insider Decisions trades per month

Total buys 52.37
Total sells 4.50
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — 6 — —
Sell — — — — — — — — — 2 — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 674.72
Revenue —
Net Income —
Free Cash Flow —
Net Debt (115.13)
Current Ratio 9.39 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio —
Fwd P/E —
P/S ratio 0.00
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth —
Next Y EPS Growth —
Next Y revenue growth —
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2017 1.71
1.71
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 2026 Q'26
Cash — — — — 115
Receivables — — — — —
Inventory — — — — —
Other — — — — —
— — — — 118
2023 2024 2025 2026 Q'26
Payables — — — — 6
ST’ Debt — — — — —
Other — — — — —
— — — — 13

Compound Annual Growth %

10y 5y 3y
Sales — — —
Cash Flow — — —
Earnings — — —
Book Value — — —

Revenue $m

Year
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Year
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Year
Fiscal quarters ending in the months shown.

EPS $

Year
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — — — — — —

Analyst estimates 2026–2028

Powerpack
High — — — — — — — — — —
People
People Employees — — — — — — — — — 44
Revenue/emp, $m — — — — — — — — — 0.00
Income, $m
Income, $m Revenue — — — — — — — — — —
Gross margin, % — — — — — — — — — —
EBT — — — — — — — — — —
EBT margin, % — — — — — — — — — —
Net income — — — — — — — — — 0
Depreciation — — — — — — — — — —
Per share, $
Per share, $ Revenue — — — — — — — — — —
Earnings — — — — — — — — — —
Cash flow — — — — — — — — — —
Capex — — — — — — — — — —
Free cash flow — — — — — — — — — —
Book value — — — — — — — — — —
Shares, m — — — — — — — — — —
Valuation, ×
Valuation, × P/E — — — — — — — — — —
P/S — — — — — — — — — —
P/B — — — — — — — — — —
EV/Sales — — — — — — — — — —
EV/FCF — — — — — — — — — —
Cash, $m
Cash, $m Operating cash flow — — — — — — — — — —
Capex — — — — — — — — — —
Free cash flow — — — — — — — — — —
Balance, $m
Balance, $m Working capital — — — — — — — — — —
Total debt — — — — — — — — — —
Net debt — — — — — — — — — —
Shareholders’ equity — — — — — — — — — —
Returns, %
Returns, % ROA — — — — — — — — — —
ROIC — — — — — — — — — —
ROE — — — — — — — — — —
Negative figures in brackets.

All 10 years →

Latest quarter Jun 2026 · fundamentals updated 29 Sep 2026

Charts ten years each

Attovia Therapeutics, Inc. vs peers (Q) = latest quarter vs a year earlier

No peers yet.

Attovia Therapeutics, Inc. (ATTO) Latest News

stockrow.com/ATTO · Data as of Sep 29, 2026 · For information only; not investment advice. · © 2026 stockrow.com